Donate
Cancer Trials Ireland > ESMO

ESMO

ESMO Congress 2025: participation from Ireland

This page highlights sessions at ESMO Congress 2025 featuring Irish investigators, clinicians, researchers and collaborators. The list reflects sessions we are currently aware of and may not be exhaustive. We warmly encourage delegates to attend and support colleagues wherever possible. Timings and locations for each session can be found by following the links below.

Oral Presentations

291O – DESTINY-Breast11: Neoadjuvant trastuzumab deruxtecan alone (T-DXd) or followed by paclitaxel + trastuzumab + pertuzumab (T-DXd-THP) vs SOC for high-risk HER2+ early breast cancer (eBC)

Catherine M. Kelly (Dublin, Ireland)

Proffered paper session 2: GI tumours, upper digestive

Integrating and sequencing locoregional and systemic treatment in hepatobiliary cancers

Maeve A. Lowery (Dublin, Ireland)

Climate action for your clinic

Seamus O'Reilly (Cork, Ireland)

296O – Risk of recurrence (ROR) after neoadjuvant ribociclib plus ET in clinically high-risk ER+/HER2− BC: Preliminary analysis of the SOLTI-RIBOLARIS trial

ADCs in early stage breast cancer: New agents, new toxicities

Roisin M. Connolly (Cork, Ireland, MD)

2799O – Patient-level analysis of pneumonitis from clinical trials of nivolumab-based regimens in solid tumours

Management of rarer toxicities of systemic therapy

Optimal ADC use in NSQ metastatic NSCLC without actionable genomic alterations

The biggest twists in my career

Jarushka Naidoo (Dublin, Ireland)

Breaking boundaries in pancreatic cancer – Emerging role of liquid biopsy in early and advanced disease

Grainne M. O’Kane (Dublin, Ireland)

LBA86 – Randomised phase III trial of androgen deprivation therapy (ADT) with radiation therapy with or without enzalutamide for high risk, clinically localised prostate cancer: ENZARAD (ANZUP 1303)

Paul J. Kelly (Cork, Ireland)

What to de-escalate and for which breast patients? De-escalation in breast surgery, radiation and systemic treatment – View of a Surgeon

Aoife Lowery (Galway, Ireland)

CN53 – Ageing with cancer: Exploring the nature, influences, and experiences of unmet needs among older adult cancer survivors

Janice Richmond (Letterkenny, Ireland)

Diversity and equity in cancer care

 

Anne-Marie Baird (Dublin, Ireland)

Tumour-agnostic anticancer therapies: Ready for prime time?

Accelerating tumour agnostic therapies

Niamh Coleman (Dublin, Ireland)

Artificial Intelligence in cancer nursing – Practical uses, ethical boundaries, and academic support

Mark Dornan (Belfast, United Kingdom)

Supportive care, symptom management and integrative oncology

Maura Dowling (Galway, Ireland)

Supporting early breast cancer patients in their drug adherence journey

Elizabeth Meade (Tullamore, Ireland)

Opportunities for targeting Glucagon Like Peptide -1 (GLP-1) in cancer prevention and treatment

Donal O’ Shea (Dublin, Ireland)

LBA14 – Adjuvant ribociclib (RIB) plus nonsteroidal aromatase inhibitor (NSAI) in patients (pts) with HR+/HER2− early breast cancer (EBC): NATALEE 5-year outcomes

John P. Crown (Dublin, Ireland)

Overview of AI and use of AI in academic writing

Polat Goktas (Dublin, Ireland)

Towards better outcomes: Developing and testing a co-designed pre-radiotherapy exercise programme for NSCLC

Matthew Beggs (Belfast, United Kingdom)

LBA12 – 5-year follow-up results from the POSITIVE (Pregnancy Outcome and Safety of Interrupting Therapy for Women with Endocrine Responsive Breast Cancer) trial

Trial open in Ireland

1317O – Results from CompARE phase III RCT: Neoadjuvant durvalumab plus chemoradiotherapy (CRT) followed by adjuvant durvalumab immunotherapy (IO) vs CRT alone in intermediate and high-risk oropharyngeal cancer (OPC)

Trial open in Ireland

LBA3 – Pembrolizumab vs placebo plus weekly paclitaxel ± bevacizumab in platinum-resistant recurrent ovarian cancer: Results from the randomized double-blind phase III ENGOT-ov65/KEYNOTE-B96 study

Trial open in Ireland

1064O – ICON8B: GCIG phase III randomised trial comparing first-line weekly dose-dense chemotherapy + bevacizumab to three-weekly chemotherapy + bevacizumab in high-risk stage III-IV epithelial ovarian cancer (EOC): Final overall survival (OS) analysis

Trial open in Ireland

Posters

Starting Saturday, 18 October, paper posters will be available in Hall 25 for one full day, with Poster Lunches scheduled from 12:00 to 12:45. Days are indicated below. ePosters will be available onsite on searchable screens in Hall 25 and via the ESMO Virtual Congress Platform starting Saturday, 18 October at 9am.

Full list of posters
2474P – Identification of a novel cluster of patients with prostate cancer in Japan with improved quality of life – results of the largest international digital survey of people affected by prostate cancer. Joe O’Sullivan (Belfast, United Kingdom) (Saturday)
2025TiP – ARTEMIDE-Lung04: A phase III, randomised, double-blind, global study of rilvegostomig or pembrolizumab monotherapy as first-line (1L) treatment for patients with metastatic non-small cell lung cancer (mNSCLC) and programmed cell death ligand-1 (PD-L1) expression ≥50%. Jarushka Naidoo (Dublin, Ireland) (Saturday)
1166P – Tisotumab vedotin plus carboplatin or pembrolizumab in recurrent or metastatic cervical cancer: 5-year results from the innovaTV 205/GOG-3024/ENGOT-cx8 study. Dearbhaile C. Collins (Cork, Ireland) (Saturday)
2483P – PCPro, plasma lipid biomarker, in metastatic hormone-sensitive prostate cancer (mHSPC): from research to clinical implementation in the ENZAMET trial (ANZUP 1304). Raymond McDermott (Dublin, Ireland) (Saturday)
2519TiP – EORTC GUCG 2238 De-escalate: A pragmatic trial to revisit intermittent androgen-deprivation therapy in metastatic hormone-naïve prostate cancer in the era of new AR pathway inhibitors. Raymond McDermott (Dublin, Ireland) (Saturday)
3149P – A Pan-European survey of irAEs: Clinical practice and models-of-care in 32 countries. Maggie L. O’Connor (Dublin, Ireland) (Saturday)
2308P – The triple planetary crisis: Implications for Ireland’s next national cancer strategy. Hailey K. Carroll (Dublin, Ireland) (Sunday)
2857P – Vasomotor symptom alleviation through acupuncture in patients with prostate cancer: results from the VASAPRO pilot study. Zain Ul Abedin (Cork, Ireland) (Sunday)
2363P – Modelling the cost of BRCA testing strategies in ovarian cancer: Integrated vs reflex testing. Ciara S. McNevin (Dublin, Ireland) (Sunday)
421TiP –OPTImaL: Optimisation of treatment for patients with low stage triple-negative breast cancer with high stromal tumor-infiltrating lymphocytes. Adrianne L. Rolfes (Amsterdam, Netherlands) (Monday)
148P – Advancing federated sharing of cancer clinical and genomic data across Europe: The 1+Million Genomes Cancer Working Group Minimal Set for Cancer. Abhishek Nayak (Limerick, Ireland) (Monday)
2994P – Insights into rare cancers: Characterizing the genomic landscape of anaplastic thyroid cancer. Ruth Hutch (Limerick, Ireland) (Monday)
376P – Oncotype-DX recurrence score (ODX RS)-guided management and long-term clinical outcomes of Irish women with node-negative (N0), oestrogen-positive (ER+), early breast cancer (EBC). Hailey K. Carroll (Dublin, Ireland) (Monday)
2048eP – Real-world survival outcomes in advanced non-small cell lung cancer (NSCLC) with driver mutations: A study from Ireland South region. Julie Twomey (Cork, Ireland) (ePoster)
427eP – Analysis of diagnostic efficacy of tomosynthesis and mammogram in male breast cancer. Abeera Mehmood (Cork, Ireland) (ePoster)
892eP – Emerging trends of early-onset colorectal cancer observed in an Irish cohort. Alice Talbot (Dublin, Ireland) (ePoster)
107eP – Safety of ivosidenib in patients with mIDH1 CCA: Updated results from the phase IIIb ProvIDHe study. Raymond McDermott (Dublin, Ireland) (ePoster)